Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

Stopped early · Phase 1

Conditions studied: Solid Tumor

In brief

This is a Phase 1, multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) in adult patients with advanced solid tumors.

Key facts

Study ID

NCT04931823

Run by

Conjupro Biotherapeutics, Inc.

People needed

34

Starts

2021-03-24

Expected to finish

2024-08-26

Last updated by the study team

2026-04-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of California Los Angeles — Los Angeles, California, United States
• Yale University School of Medicine - Yale Cancer Center — New Haven, Connecticut, United States
• Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada, United States
• Carolina BioOncology Institute — Huntersville, North Carolina, United States
• The Cleveland Clinic Foundation — Lyndhurst, Ohio, United States
• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
• Texas Oncology - Baylor Charles A. Sammons Cancer Center — Dallas, Texas, United States
• Virginia Cancer Specialist — Fairfax, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.